BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Lee FY, Huo TI. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112-119. [PMID: 22806819 DOI: 10.1002/hep.25950] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014; 20(28): 9217-9228 [PMID: 25071314 DOI: 10.3748/wjg.v20.i28.9217] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
2 Zhao S, Zhang X, Wang M, Tan K, Dou W, Fan Q, Li H, Du X, Liu L. Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Ann Transl Med 2020;8:586. [PMID: 32566613 DOI: 10.21037/atm.2020.02.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Khalaf MH, Sundaram V, AbdelRazek Mohammed MA, Shah R, Khosla A, Jackson K, Desai M, Kothary N. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma. Radiology. 2019;290:254-261. [PMID: 30299233 DOI: 10.1148/radiol.2018180257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
4 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Huang YH, Lei HJ, He YJ, Hou MC, Huo TI. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. Am J Clin Oncol. 2019;42:698-704. [PMID: 31335351 DOI: 10.1097/coc.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
5 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
6 Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, Kitamura K, Kagaya T, Sakai Y, Mizukoshi E. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res. 2015;45:949-959. [PMID: 25319848 DOI: 10.1111/hepr.12436] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hsu C, Liu P, Lee Y, Hsia C, Huang Y, Chiou Y, Tsai Y, Nagaria TS, Huo T. Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. Ann Surg Oncol 2015;22:1324-31. [DOI: 10.1245/s10434-014-4151-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
8 Seshadri RM, Baker EH, Templin M, Swan RZ, Martinie JB, Vrochides D, Iannitti DA. Outcomes of surgical resection and loco-regional therapy in patients with stage 3A hepatocellular carcinoma: a retrospective review from the national cancer database. HPB (Oxford) 2015;17:964-8. [PMID: 26271743 DOI: 10.1111/hpb.12466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
9 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018;8:4773. [PMID: 29555927 DOI: 10.1038/s41598-018-22923-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
10 Zhang L, Wang Z, Li M, Sun P, Bai T, Wang W, Bai H, Gou J, Wang Z. HCG18 Participates in Vascular Invasion of Hepatocellular Carcinoma by Regulating Macrophages and Tumor Stem Cells. Front Cell Dev Biol 2021;9:707073. [PMID: 34527669 DOI: 10.3389/fcell.2021.707073] [Reference Citation Analysis]
11 Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW, Lin HC, Huo TI. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin Gastroenterol 2014;48:734-41. [PMID: 24100755 DOI: 10.1097/MCG.0b013e3182a8a254] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
12 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
13 Orman ES, Ghabril M, Chalasani N. Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016;14:1189-1195.e1. [PMID: 27046483 DOI: 10.1016/j.cgh.2016.03.036] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
14 Liu PH, Hsia CY, Lee YH, Hsu CY, Huang YH, Su CW, Lee RC, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol. 2015;111:404-409. [PMID: 25643842 DOI: 10.1002/jso.23854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
15 Borzio M, Dionigi E, Rossini A, Marignani M, Sacco R, De Sio I, Bertolini E, Francica G, Giacomin A, Parisi G, Vicari S, Toldi A, Salmi A, Boccia S, Mitra M, Fornari F. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology. 2018;67:2215-2225. [PMID: 29165831 DOI: 10.1002/hep.29662] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
16 Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069-3076. [PMID: 24728740 DOI: 10.1245/s10434-014-3704-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
17 Kim GA, Kim HI, Chang S, An J, Lee D, Lee HC, Han S, Shim JH. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma. Am J Clin Oncol 2019;42:555-63. [PMID: 31135382 DOI: 10.1097/COC.0000000000000555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria: Sarcopenia assessment criteria in liver disease. Hepatol Res 2016;46:951-63. [DOI: 10.1111/hepr.12774] [Cited by in Crossref: 197] [Cited by in F6Publishing: 201] [Article Influence: 32.8] [Reference Citation Analysis]
19 Hsu CY, Liu PH, Hsia CY, Lee YH, Nagaria TS, Lee RC, Lin HC, Huo TI. Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. Ann Surg Oncol. 2016;23:994-1002. [PMID: 26487000 DOI: 10.1245/s10434-015-4929-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
20 Chuncharunee A, Siramolpiwat S. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment. Asian Pac J Cancer Prev 2017;18:1697-701. [PMID: 28670891 DOI: 10.22034/APJCP.2017.18.6.1697] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Huo TI, Liu PH, Hsu CY. Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors. J Hepatol 2020;72:1032-3. [PMID: 32122721 DOI: 10.1016/j.jhep.2019.12.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Martini DJ, Kline MR, Liu Y, Shabto JM, Carthon BC, Russler GA, Yantorni L, Hitron EE, Caulfield S, Goldman JM, Harris WB, Kucuk O, Master VA, Bilen MA. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treat Res Commun 2021;28:100393. [PMID: 34029879 DOI: 10.1016/j.ctarc.2021.100393] [Reference Citation Analysis]
23 Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825-1833. [PMID: 24499831 DOI: 10.1245/s10434-014-3510-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
24 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Hsu CY, Liu PH, Ho SY, Huang YH, Lee YH, Chiou YY, Hsieh TH, Fang T, Tsai YJ, Hou MC, Huo TI. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS One 2017;12:e0188031. [PMID: 29125877 DOI: 10.1371/journal.pone.0188031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
26 Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2  cm in a Propensity Score Model. Ann Surg 2016;263:538-45. [PMID: 25775062 DOI: 10.1097/SLA.0000000000001178] [Cited by in Crossref: 86] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
27 Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Hepatology. 2017;65:122-133. [PMID: 27770556 DOI: 10.1002/hep.28881] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
28 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Tsai YJ, Nagaria TS, Lin HC, Huo TI. Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4: A Propensity Score Analysis. J Clin Gastroenterol 2015;49:878-84. [PMID: 25710525 DOI: 10.1097/MCG.0000000000000300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
30 Gmür A, Kolly P, Knöpfli M, Dufour J. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. Liver Int 2018;38:1468-74. [DOI: 10.1111/liv.13711] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
31 Panaro F, Ramos J, Gallix B, Mercier G, Herrero A, Niampa H, Pageaux G, Navarro F. Hepatic artery complications following liver transplantation. Does preoperative chemoembolization impact the postoperative course? Clin Transplant 2014;28:598-605. [DOI: 10.1111/ctr.12358] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
32 Liu P, Lee Y, Hsu C, Hsia C, Huang Y, Chiou Y, Lin H, Huo T. Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. J Gastrointest Surg 2014;18:1623-31. [DOI: 10.1007/s11605-014-2546-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
33 Barman PM, Su GL. Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2016;7:32-35. [PMID: 31041024 DOI: 10.1002/cld.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Rich NE, Phen S, Desai N, Mittal S, Yopp AC, Yang JD, Marrero JA, Iyengar P, Infante RE, Singal AG. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01036-3. [PMID: 34555519 DOI: 10.1016/j.cgh.2021.09.022] [Reference Citation Analysis]
35 Huo TI, Hsu CY, Liu PH. Performance status in patients with HCC: New kid on the block. J Hepatol 2017;67:1352-3. [PMID: 28803954 DOI: 10.1016/j.jhep.2017.06.036] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Vishnevsky VA, Ayvazyan KA, Ikramov RZ, Ionkin DA, Zhavoronkova OI, Stepanova YA, Varava AB, Kovalenko YA, Zharikov YO, Goncharov AB, Olifir AA, Pakhomova AY, Bugaev SA, Zhao AV. Modern principles of hepatocellular carcinoma treatment. Ann hir gepatol 2020;25:15-26. [DOI: 10.16931/1995-5464.2020215-26] [Reference Citation Analysis]
37 Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, Lee RC, Lin HC, Huo TI. Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One. 2016;11:e0155588. [PMID: 27176037 DOI: 10.1371/journal.pone.0155588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
38 Wu H, Xing H, Liang L, Huang B, Li C, Lau WY, Zhou Y, Gu W, Wang H, Chen T, Zhang Y, Zeng Y, Pawlik TM, Wang M, Wu M, Shen F, Yang T. Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. European Journal of Surgical Oncology 2019;45:2360-8. [DOI: 10.1016/j.ejso.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Hsu CY, Lee YH, Liu PH, Hsia CY, Huang YH, Lin HC, Chiou YY, Lee FY, Huo TI. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One 2014;9:e89373. [PMID: 24586728 DOI: 10.1371/journal.pone.0089373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
40 Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1322-1331 [PMID: 29359015 DOI: 10.4254/wjh.v9.i36.1322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
41 Kanbayashi Y, Hosokawa T, Yasui K, Hongo F, Yamaguchi K, Moriguchi M, Miki T, Itoh Y. Predictive factors for sorafenib-induced hand–foot skin reaction using ordered logistic regression analysis. American Journal of Health-System Pharmacy 2016;73:e18-23. [DOI: 10.2146/ajhp150129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688. [PMID: 25860213 DOI: 10.1097/md.0000000000000688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
43 Ho SY, Liu PH, Hsu CY, Chiou YY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Sci Rep. 2018;8:843. [PMID: 29339752 DOI: 10.1038/s41598-018-19251-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
44 Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, Salloum C, Luciani A, Azoulay D. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015;261:1173-83. [PMID: 24950264 DOI: 10.1097/SLA.0000000000000743] [Cited by in Crossref: 174] [Cited by in F6Publishing: 85] [Article Influence: 29.0] [Reference Citation Analysis]
45 Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep 2017;7:42577. [PMID: 28209963 DOI: 10.1038/srep42577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
46 Hsu CY, Liu PH, Ho SY, Huang YH, Lee YH, Lee RC, Nagaria TS, Hou MC, Huo TI. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver Int 2018;38:1803-11. [PMID: 29608816 DOI: 10.1111/liv.13748] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
47 Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. Eur J Gastroenterol Hepatol 2018;30:44-53. [PMID: 29076939 DOI: 10.1097/MEG.0000000000001005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (Baltimore) 2015;94:e1223. [PMID: 26200647 DOI: 10.1097/MD.0000000000001223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Marasco G, Serenari M, Renzulli M, Alemanni LV, Rossini B, Pettinari I, Dajti E, Ravaioli F, Golfieri R, Cescon M, Festi D, Colecchia A. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol 2020;55:927-43. [PMID: 32748172 DOI: 10.1007/s00535-020-01711-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
50 Hsu CY, Liu PH, Ho SY, Hsia CY, Kudaravalli P, Lee YH, Chiou YY, Tsai YJ, Huang YH, Huo TI. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289. [PMID: 29540157 DOI: 10.1186/s12885-018-4202-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Bezinover D, Geyer NR, Dahmus J, Chinchilli VM, Stine JG. A decline in functional status while awaiting liver transplantation is predictive of increased post-transplantation mortality. HPB (Oxford) 2021:S1365-182X(21)01664-6. [PMID: 34772623 DOI: 10.1016/j.hpb.2021.10.008] [Reference Citation Analysis]
52 Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC. Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore). 2015;94:e1929. [PMID: 26512620 DOI: 10.1097/md.0000000000001929] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
53 Wörns MA, Galle PR. Reply to: "Performance status in patients with HCC: New kid on the block". J Hepatol 2017;67:1353-5. [PMID: 28803952 DOI: 10.1016/j.jhep.2017.07.029] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Hu H, Chen GF, Yuan W, Wang JH, Zhai B. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia 2018;34:1351-8. [PMID: 29720001 DOI: 10.1080/02656736.2018.1462536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
55 Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Lee FY, Huo TI. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol 2013;20:2035-42. [PMID: 23306955 DOI: 10.1245/s10434-012-2847-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
56 Borzio M, Dionigi E, Vitale A, Rossini A, Marignani M, Fornari F, Vicari S, De Sio I, Farinati F, Bertolini E, Oliveri F, Leandro G, Francica G, Mitra M, Omazzi B, Boccia S, Salmi A, Toldi A, Sacco R. Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. Liver Int 2017;37:1184-92. [DOI: 10.1111/liv.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
57 Cho HJ, Kim SS, Kang SY, Yang MJ, Noh CK, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY; Korean Liver Cancer Association. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status. Gut Liver 2019;13:557-68. [PMID: 31023007 DOI: 10.5009/gnl18444] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
58 Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2016;64:601-608. [PMID: 26551516 DOI: 10.1016/j.jhep.2015.10.029] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 16.4] [Reference Citation Analysis]
59 Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg 2016;20:2002-9. [PMID: 27714643 DOI: 10.1007/s11605-016-3285-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
60 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
61 Ho SY, Yuan MH, Chen CC, Liu PH, Hsu CY, Huang YH, Lei HJ, Lee RC, Huo TI. Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. Dig Dis Sci 2020;65:3389-402. [PMID: 31955286 DOI: 10.1007/s10620-020-06053-4] [Reference Citation Analysis]
62 Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: A propensity score analysis. Medicine (Baltimore). 2014;93:e264. [PMID: 25526453 DOI: 10.1097/md.0000000000000264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
63 Xu Y, Zhang Y, Wang X, Kang J, Liu X. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Cancer 2019;19:168. [PMID: 30795756 DOI: 10.1186/s12885-019-5375-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
64 Li H, Li B, Wei Y, Yan L, Wen T, Wang W, Yang J, Lu W, Xu M. Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience. Clin Res Hepatol Gastroenterol 2015;39:451-7. [PMID: 25623860 DOI: 10.1016/j.clinre.2014.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
65 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
66 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 10.6] [Reference Citation Analysis]
67 Honjo K, Komiya K, Kan T, Uchida S, Goto A, Takikawa S, Yoshimatsu T, Wong ZSY, Takahashi O, Kadota JI. The impact of performance status on tuberculosis-related death among elderly patients with lung tuberculosis: A competing risk regression analysis. J Infect Chemother 2020;26:69-75. [PMID: 31375456 DOI: 10.1016/j.jiac.2019.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Chen C, Liu P, Lee Y, Tsai Y, Hsu C, Huang Y, Chiou Y, Huo T. Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation: Radiofrequency ablation in renal insufficiency. J Gastroenterol Hepatol 2015;30:192-8. [DOI: 10.1111/jgh.12669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Lin HC, Chiou YY, Lee FY, Huo TI. Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One. 2015;10:e0118825. [PMID: 25738614 DOI: 10.1371/journal.pone.0118825] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
70 Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol 2022. [PMID: 35381853 DOI: 10.1007/s00330-022-08716-4] [Reference Citation Analysis]
71 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Lee RC, Hou MC, Huo TI. ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. J Gastrointest Oncol 2021;12:722-34. [PMID: 34012661 DOI: 10.21037/jgo-20-332] [Reference Citation Analysis]
72 Marta GN, da Fonseca LG, Braghiroli MI, Moura F, Hoff PM, Sabbaga J. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. Clinics (Sao Paulo) 2021;76:e2498. [PMID: 33503195 DOI: 10.6061/clinics/2021/e2498] [Reference Citation Analysis]
73 Shousha HI, Abdelaziz AO, Nabeel MM, Omran DA, Abdelmaksoud AH, Elbaz TM, Salah A, Harb STE, Hosny KA, Osman A, Atef M, Gaber A, Zayed NA, Yosry AA, Leithy R. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade. Pathog Glob Health 2021;:1-9. [PMID: 34494507 DOI: 10.1080/20477724.2021.1975081] [Reference Citation Analysis]
74 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
75 Liu PH, Lee YH, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol. 2014;21:3835-3843. [PMID: 24903236 DOI: 10.1245/s10434-014-3831-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
76 Tamura S, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Murayama S, Uesaka K. A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma. Surg Today 2020;50:369-78. [PMID: 31602531 DOI: 10.1007/s00595-019-01888-5] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Chen C, An L, Cheng Y, Luo X, Li Z, Liu X. Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2020;10:1404. [PMID: 32983970 DOI: 10.3389/fonc.2020.01404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Liu P, Hsu C, Hsia C, Lee Y, Huang Y, Su C, Lee F, Lin H, Huo T. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer 2016;63:25-33. [DOI: 10.1016/j.ejca.2016.04.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
79 Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U;  Italian Liver Cancer (ITA. LI.CA) group. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol. 2015;62:617-624. [PMID: 25450706 DOI: 10.1016/j.jhep.2014.10.037] [Cited by in Crossref: 96] [Cited by in F6Publishing: 107] [Article Influence: 12.0] [Reference Citation Analysis]
80 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One 2014;9:e99115. [PMID: 24906132 DOI: 10.1371/journal.pone.0099115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
81 Hsu CY, Liu PH, Hsia CY, Lee YH, Al Juboori A, Lee RC, Lin HC, Huo TI. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver Int. 2016;36:1498-1506. [PMID: 26972815 DOI: 10.1111/liv.13114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
82 Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015;6:394-402. [PMID: 25767611 DOI: 10.7150/jca.11212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
83 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Lee RC, Tsai PH, Hou MC, Huo TI. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 2021. [PMID: 34159651 DOI: 10.1111/jgh.15593] [Reference Citation Analysis]
84 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [DOI: 10.1002/hep.29668] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
85 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
86 Zhang W, Zhangyuan G, Wang F, Zhang H, Yu D, Wang J, Jin K, Yu W, Liu Y, Sun B. High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. J Cancer 2019;10:3494-500. [PMID: 31293654 DOI: 10.7150/jca.29499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
87 Haskal ZJ. Editor's suggested readings in interventional oncology. J Vasc Interv Radiol 2013;24:1165-6. [PMID: 23885914 DOI: 10.1016/j.jvir.2013.05.068] [Reference Citation Analysis]
88 Li M, Fu S, Zhu Y, Liu Z, Chen S, Lu L, Liang C. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget 2016;7:13248-59. [PMID: 26910890 DOI: 10.18632/oncotarget.7467] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
89 Wang SF, Chen XP, Chen ZS, Wei L, Dong SL, Guo H, Jiang JP, Teng WH, Huang ZY, Zhang WG. Left Lobe Auxiliary Liver Transplantation for End-stage Hepatitis B Liver Cirrhosis. Am J Transplant 2017;17:1606-12. [PMID: 27888553 DOI: 10.1111/ajt.14143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Uhlig J, Sellers CM, Stein SM, Kim HS. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol. 2019;29:2679-2689. [PMID: 30560364 DOI: 10.1007/s00330-018-5902-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
91 Jundt MC, Owen RL, Thompson SM, Fleming CJ, Stockland AH, Andrews JC. MELD-Na > 16 is associated with high peri-procedural and short-term mortality in patients with ruptured hepatocellular carcinoma treated with emergent transarterial embolization. Abdom Radiol (NY) 2021. [PMID: 34633495 DOI: 10.1007/s00261-021-03306-2] [Reference Citation Analysis]
92 Hsu CY, Liu PH, Hsia CY, Lee YH, Nagaria TS, Lee RC, Ho SY, Hou MC, Huo TI. A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. Sci Rep 2017;7:7914. [PMID: 28801646 DOI: 10.1038/s41598-017-08382-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
93 Taylor AC, Maddirela D, White SB. Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America 2019;28:731-43. [DOI: 10.1016/j.soc.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015; 7(11): 1521-1529 [PMID: 26085911 DOI: 10.4254/wjh.v7.i11.1521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
95 Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
96 Lué A, Serrano MT, Bustamante FJ, Iñarrairaegui M, Arenas JI, Testillano M, Lorente S, Gil C, de la Torre M, Gomez A, Sangro B. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget 2017;8:103077-86. [PMID: 29262546 DOI: 10.18632/oncotarget.21528] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
97 Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. Liver Cancer. 2017;6:236-249. [PMID: 28626734 DOI: 10.1159/000472262] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
98 Kim GH, Kim JH, Shim JH, Ko HK, Chu HH, Shin JH, Yoon HK, Ko GY, Gwon DI. Chemoembolization for Single Large Hepatocellular Carcinoma with Preserved Liver Function: Analysis of Factors Predicting Clinical Outcomes in a 302 Patient Cohort. Life (Basel) 2021;11:840. [PMID: 34440584 DOI: 10.3390/life11080840] [Reference Citation Analysis]
99 Singal AG, Zhang P, Waljee AK, Ananthakrishnan L, Parikh ND, Sharma P, Barman P, Krishnamurthy V, Wang L, Wang SC, Su GL. Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. Clin Transl Gastroenterol 2016;7:e172. [PMID: 27228403 DOI: 10.1038/ctg.2016.31] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
100 Xu X, Lau WY, Yang T. The Updated BCLC Staging System Needs Further Refinement: A Surgeon’s Perspective. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.002] [Reference Citation Analysis]
101 Edeline J, Blanc JF, Campillo-Gimenez B, Ma YT, King J, Faluyi O, Mathurin J, Ghazi S, Palmer DH, Meyer T. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer 2017;86:135-42. [PMID: 28987770 DOI: 10.1016/j.ejca.2017.08.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
102 Shousha HI, Fouad R, Elbaz TM, Sabry D, Mahmoud Nabeel M, Hosni Abdelmaksoud A, Mahmoud Elsharkawy A, Soliman ZA, Habib G, Abdelaziz AO. Predictors of recurrence and survival of hepatocellular carcinoma: A prospective study including transient elastography and cancer stem cell markers. Arab J Gastroenterol 2020;21:95-101. [PMID: 32439234 DOI: 10.1016/j.ajg.2020.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Tsai PH, Chou SJ, Lee RC, Hou MC, Huo TI. Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res 2021. [PMID: 34038019 DOI: 10.1111/hepr.13671] [Reference Citation Analysis]
104 Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Sci. 2016;107:1263-1269. [PMID: 27315783 DOI: 10.1111/cas.12992] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
105 Wallace D, Cowling T, Mcphail MJ, Brown SE, Aluvihare V, Suddle A, Auzinger G, Heneghan MA, Rowe IA, Walker K, Heaton N, Meulen J, Bernal W. Assessing the Time‐Dependent Impact of Performance Status on Outcomes After Liver Transplantation. Hepatology 2020;72:1341-52. [DOI: 10.1002/hep.31124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
106 Burton A, Balachandrakumar VK, Driver RJ, Tataru D, Paley L, Marshall A, Alexander G, Rowe IA, Palmer DH, Cross TJS; HCC-UK/BASL/NCRAS Partnership. Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England. Br J Cancer 2021. [PMID: 34837073 DOI: 10.1038/s41416-021-01509-4] [Reference Citation Analysis]
107 Wang T, Zhang J, Wang W, Yang X, Kong J, Shen S, Wang W. Development and Validation of Nomograms for Predicting Cancer-Specific Survival in Elderly Patients with Intrahepatic Cholangiocarcinoma After Liver Resection: A Competing Risk Analysis. Cancer Manag Res 2020;12:11015-29. [PMID: 33173335 DOI: 10.2147/CMAR.S272797] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465. [PMID: 26059447 DOI: 10.1186/s12885-015-1480-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
109 Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014;93:e348. [PMID: 25546689 DOI: 10.1097/MD.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
110 Zhao S, Dou W, Fan Q, Hu J, Li H, Zhang X, Zhang Q, Liu L. Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma. Ann Transl Med 2020;8:587. [PMID: 32566614 DOI: 10.21037/atm.2020.02.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24:1786-1792. [PMID: 23508822 DOI: 10.1093/annonc/mdt072] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 8.0] [Reference Citation Analysis]
112 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
114 Huo TI, Ho SY, Hsu CY. Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail? Clin Gastroenterol Hepatol 2021:S1542-3565(21)01365-3. [PMID: 34971807 DOI: 10.1016/j.cgh.2021.12.041] [Reference Citation Analysis]
115 Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385-399. [PMID: 26662476 DOI: 10.1111/apt.13485] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
116 Ueno H, Hase K, Hashiguchi Y, Shimazaki H, Tanaka M, Miyake O, Masaki T, Shimada Y, Kinugasa Y, Mori Y, Kishimoto M, Kameoka S, Sato Y, Matsuda K, Nakadoi K, Shinto E, Nakamura T, Sugihara K. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. Am J Surg Pathol 2014;38:197-204. [PMID: 24418853 DOI: 10.1097/PAS.0000000000000113] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
117 Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, Hu J, Feng D. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med 2020;8:583. [PMID: 32566610 DOI: 10.21037/atm.2020.03.71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
118 Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA. LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med. 2016;13:e1002006. [PMID: 27116206 DOI: 10.1371/journal.pmed.1002006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
119 Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Tojima H, Shimada Y, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatol Res. 2020;50:382-395. [PMID: 31760660 DOI: 10.1111/hepr.13460] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
120 Ho SY, Hsu CY, Liu PH, Ko CC, Huang YH, Su CW, Lee RC, Hou MC, Huo TI. Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers (Basel) 2020;12:E1130. [PMID: 32366000 DOI: 10.3390/cancers12051130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]